Legacy Capital Group California Inc. Invests $162,000 in Takeda Pharmaceutical Company Limited (NYSE:TAK)

Legacy Capital Group California Inc. bought a new position in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the 2nd quarter, according to its most recent disclosure with the SEC. The firm bought 10,301 shares of the company’s stock, valued at approximately $162,000.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Dimensional Fund Advisors LP raised its holdings in Takeda Pharmaceutical by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 143,115 shares of the company’s stock worth $2,359,000 after buying an additional 616 shares during the last quarter. Northwestern Mutual Wealth Management Co. raised its holdings in Takeda Pharmaceutical by 28.7% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 2,976 shares of the company’s stock worth $46,000 after buying an additional 663 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Takeda Pharmaceutical by 70.7% in the first quarter. EverSource Wealth Advisors LLC now owns 1,757 shares of the company’s stock worth $29,000 after buying an additional 728 shares during the last quarter. Checchi Capital Advisers LLC raised its holdings in Takeda Pharmaceutical by 5.5% in the second quarter. Checchi Capital Advisers LLC now owns 14,490 shares of the company’s stock worth $228,000 after buying an additional 758 shares during the last quarter. Finally, BNP Paribas Arbitrage SNC raised its holdings in Takeda Pharmaceutical by 37.5% in the second quarter. BNP Paribas Arbitrage SNC now owns 2,781 shares of the company’s stock worth $44,000 after buying an additional 759 shares during the last quarter. 2.65% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Stock Up 1.7 %

TAK opened at $13.95 on Friday. The company has a quick ratio of 0.55, a current ratio of 1.04 and a debt-to-equity ratio of 0.62. The firm has a 50 day moving average price of $14.81 and a 200-day moving average price of $15.42. Takeda Pharmaceutical Company Limited has a twelve month low of $13.19 and a twelve month high of $17.15. The stock has a market capitalization of $44.15 billion, a price-to-earnings ratio of 19.38, a PEG ratio of 4.81 and a beta of 0.64.

Takeda Pharmaceutical (NYSE:TAK) last released its quarterly earnings data on Thursday, October 26th. The company reported $0.50 earnings per share for the quarter. Takeda Pharmaceutical had a net margin of 7.35% and a return on equity of 12.36%. The firm had revenue of $6.94 billion during the quarter. Equities research analysts forecast that Takeda Pharmaceutical Company Limited will post 0.4 earnings per share for the current year.

Analyst Upgrades and Downgrades

Separately, JPMorgan Chase & Co. decreased their target price on shares of Takeda Pharmaceutical from $14.20 to $14.00 in a report on Friday, September 1st.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.